Form 8-K - Current report:
SEC Accession No. 0000950157-24-001314
Filing Date
2024-09-27
Accepted
2024-09-27 16:00:57
Documents
14
Period of Report
2024-09-27
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT form8-k.htm   iXBRL 8-K 37354
2 SECOND AMENDED AND RESTATED REVOLVING CREDIT AGREEMENT ex10-1.htm EX-10.1 1086982
  Complete submission text file 0000950157-24-001314.txt   1470536

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA vtrs-20240927.xsd EX-101.SCH 3862
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE vtrs-20240927_lab.xml EX-101.LAB 21966
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vtrs-20240927_pre.xml EX-101.PRE 16042
17 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 4054
Mailing Address 1000 MYLAN BOULEVARD CANONSBURG PA 15317
Business Address 1000 MYLAN BOULEVARD CANONSBURG PA 15317 (724) 514-1465
Viatris Inc (Filer) CIK: 0001792044 (see all company filings)

EIN.: 834364296 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39695 | Film No.: 241334784
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)